Warfarin genotyping in a single PCR reaction for microchip electrophoresis

Clinical Chemistry

Volumn 58, Issue 4, 2012, Pages 725-731

  Poe, Brian L ^a   Haverstick, Doris M ^b   Landers, James P ^a,b,c  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c University of Virginia   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; CYTOCHROME P450 2C9 2; CYTOCHROME P450 2C9 3; GENOMIC DNA; MENADIONE EPOXIDE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN;

ALLELE; AMPLIFICATION REFRACTORY MUTATION SYSTEM; ARTICLE; GENETIC SCREENING; GENOTYPE; HOSPITALIZATION; HUMAN; MICROCHIP ELECTROPHORESIS; MICROFLUIDICS; POLYMERASE CHAIN REACTION; SIGNAL NOISE RATIO; SINGLE NUCLEOTIDE POLYMORPHISM; TETRAPRIMER AMPLIFICATION REFRACTORY MUTATION SYSTEM;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BASE SEQUENCE; DNA PRIMERS; ELECTROPHORESIS, MICROCHIP; GENOTYPE; HUMANS; MICROFLUIDIC ANALYTICAL TECHNIQUES; MIXED FUNCTION OXYGENASES; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; WARFARIN;

EID: 84859364776     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2011.180356     Document Type: Article

References (31)

1. Gage BF, Lesko LJ. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis 2008;25:45-51.
2. Flockhart DA, O'Kane D, Williams MS, Watson MS, Flockhart DA, Gage B, et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 2008;10:139-50. (Pubitemid 351271726)
3. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 2006;296:1858-66. (Pubitemid 44596195)
4. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005;352:2285-93. (Pubitemid 40740552)
5. Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, et al., on behalf of the International Warfarin Pharmacogenetics Corsortium. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010;115:3827-34.
6. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bupstead S, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009;113:784-92.
7. Epstein RS, Moyer TP, Aubert RE, O'Kane DJ, Xia F, Verbrugge RR, et al. Warfarin genotyping reduces hospitalization rates: results from the MMWES (Medco-Mayo Warfarin Effectiveness Study). J Am Coll Cardiol 2010;55:2804-12.
8. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009;150:73-83.
9. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 2008;83:460-70. (Pubitemid 351272635)
10. Maurice CB, Barua PK, Simses D, Smith P, Howe JG, Stack G. Comparison of assay systems for warfarin-related CYP2C9 and VKORC1 genotyping. Clin Chim Acta 2010;411:947-54.
11. King CR, Porche-Sorbet RM, Gage BF, Ridker PM, Renaud Y, Phillips MS, Eby C. Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose. Am J Clin Pathol 2008;129:876-83.
12. Zhu J, Zhang W, Li Y, Zhang W, Wang H, Zheng W, Wang C. ARMS test for diagnosis of CYP2C9 and VKORC1 mutation in patients with pulmonary embolism in Han Chinese. Pharmacogenomics 2010;11:113-9.
13. Spohn G, Geisen C, Luxembourg B, Sittinger K, Seifried E, Bönig H. Validation of a rapid and inexpensive allele-specific amplification (ASA)-PCR genotyping assay for vitamin K antagonist pharmacogenomics. Mol Diagn Ther 2011;15:13-9.
14. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008;358:999-1008. (Pubitemid 351347099)
15. Rai AJ, Udar N, Saad R, Fleisher M. A multiplex assay for detecting genetic variations in CYP2C9, VKORC1, and GGCX involved in warfarin metabolism. Clin Chem 2009;55:823-6.
16. Aithal GP, Day CP, Kesteven PJL, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717-9. (Pubitemid 29103806)
17. Crews N, Wittwer CT, Montgomery J, Pryor R, Gale B. Spatial DNA melting analysis for genotyping and variant scanning. Anal Chem 2009;81:2053-8.
18. Huang SW, Chen HS, Wang XQ, Huang L, Xu DL, Hu XJ, et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics 2009;19:226-34.
19. Aomori T, Yamamoto K, Oguchi-Katayama A, Kawai Y, Ishidao T, Mitani Y, et al. Rapid singlenucleotide polymorphism detection of cytochrome P450 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genes for the warfarin dose adjustment by the SMart-amplification process version 2. Clin Chem 2009;55:804-12.
20. Easley CJ, Karlinsey JM, Bienvenue JM, Legendre LA, Roper MG, Feldman SH, et al. A fully integrated microfluidic genetic analysis system with sample-in-answer-out capability. Proc Natl Acad Sci U S A 2006;103:19272-7. (Pubitemid 46026023)
21. Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 1989;17:2503-16.
22. Huang MM, Arnheim N, Goodman MF. Extension of base mispairs by Taq DNA polymerase: implications for single nucleotide discrimination in PCR. Nucleic Acids Res 1992;20:4567-73.
23. Ye S, Dhillon S, Ke X, Collins AR, Day IN. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res 2001;29:E88-8.
24. Piccioli P. Multiplex tetra-primer amplification refractory mutation system PCR to detect 6 common germline mutations of the MUTYH gene associated with polyposis and colorectal cancer. Clin Chem 2006;52:739-43.
25. Okayama N, Fujimura K, Nakamura J, Suehiro Y, Hamanaka Y, Hinoda Y. Evaluation of a new efficient procedure for single-nucleotide polymorphism genotyping: tetra-primer amplification refractory mutation system-polymerase chain reaction. Clin Chem Lab Med 2004;42:13-6. (Pubitemid 38401462)
26. Entrogen. CYP2C9/VKORC1 genotyping kit-warfarin sensitivity. http://www.entrogen.com/web/cyp2c9-vkorc1-genotyping-reagents- warfarinsensitivity.php (Accessed December 2011).
27. Toubanaki DK, Christopoulos TK, Ioannou PC, Gravanis A. Visual genotyping of SNPs of drugmetabolizing enzymes by tetra-primer PCR coupled with a dry-reagent DNA biosensor. Pharmacogenomics 2009;10:495-504.
28. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000;132:365-86.
29. SantaLucia J Jr, Hicks D. The thermodynamics of DNA structural motifs. Annu Rev Biophys Biomol Struct 2004;33:415-40. (Pubitemid 38829966)
30. Kim YH, Yang I, Bae YS, Park SR. Performance evaluation of thermal cyclers for PCR in a rapid cycling condition. Biotechniques 2008;44:495-6, 498, 500 passim.
31. Easley CJ, Humphrey JAC, Landers JP. Thermal isolation of microchip reaction chambers for rapid non-contact DNA amplification. J Micromech Microeng 2007;17:1758-66.